empty

GPhC should explain rise in premises fees, says PDA

 

The Pharmacists’ Defence Association (PDA) has urged the General Pharmaceutical Council (GPhC) to explain the rationale behind its proposed increased registration fee of £365 for pharmacy premises.

The regulator's official consultation on the premises fee hike closed at the end of March, during a time when many contractors have faced financial difficulties relating to the Covid-19 pandemic.

The fee for renewal and registration is set to go from £262 to £365, an increase the PDA said would give the GPhC £1.5 million in extra income.

The PDA said it supported “the principle of a fee increase” but insisted the regulator act “in line with the Nolan Principle of Openness” and present “a full and comprehensive set of financial workings on how it has arrived at the figure of £365.”

“The GPhC should not raise fees until it can detail and demonstrate independently verifiable efficiency gains on an annual basis before coming back to registrants for any increase in fees,” the PDA said.

It also said the GPhC should not expect “year on year increases in its income as a matter of right” and community pharmacy cannot support the “guarantee of a three-year fixed increase in fee income for the GPhC.”

The PDA added: “The GPhC must provide full working models on fees showing cost allocations according to registrant type.

“(It) must provide data if it is to introduce variable fees to show how the variances would impact different groups of registrants (pharmacists/technicians/premises).”

On accreditation MPharm courses, the PDA said fees must “properly be charged to institutions and not allocated as a cost when determining pharmacist registration fees.”

It also urged the GPhC to publish the equality impact analysis from the fees increase last year and in previous years.

When contacted by Independent Community Pharmacist, a GPhC spokesperson said: “We recognise that, at the current time, the first priority of pharmacy professionals and organisations is to focus on patient safety and dealing with the coronavirus outbreak. 

“We are carefully considering all responses to the consultation and will publish a summary of the responses, along with an explanation of the decision we have taken, in due course.”




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Independent Pharmacist's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.